EUROAPI overview

Press Release Paris – October 16, 2024 – Olivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024, and will be a member of the Executive Committee. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. “I am delighted to welcome Olivier, a seasoned Chief Financial Officer with extensive experience in the industrial sector. He will play a decisive role in implementing our...

Press Release Paris - 15 October 2024 - EUROAPI today announces the closing of the refinanced Credit Revolving Facility (RCF) and the Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi, thus completing the financing of its FOCUS-27 strategic plan. About EUROAPI EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200...

Press Release Paris, 30th July 2024 Net Sales down 9.6% year-on-year – Core EBITDA margin at 10.6% Accelerated commercial momentum with clients other than Sanofi, with Net Sales up 2.9%, excluding the Brindisi site, where production was temporarily suspended Enhanced effectiveness across the entire organization, with sizeable improvements in industrial efficiencies €10 million Free Cash Flow before financing, driven by strengthened financial discipline FY 2024 guidance confirmed " Our H1...

Press Release A 5-year manufacturing contract to support the FOCUS-27 project sales trajectory This contract highlights EUROAPI’s know-how and the reliability of its premium Contract Manufacturing Organization services to customers Paris – May 23, 2024 – EUROAPI announces today that it has entered into a Contract Manufacturing Organization (CMO) agreement with a global animal health company. As part of this collaboration, EUROAPI will supply its client with a key veterinary product. The...

Press Release Paris – April 5, 2024 – EUROAPI announces the publication of its 2023 Universal Registration Document, filed with the French Autorité des marchés financiers (AMF) on April 5, 2024. The 2023 Universal Registration Document includes in particular: The annual financial report; The Board of Directors’ corporate governance report; The information about social, environmental, and societal responsibility (including the extra-financial performance declaration); The statutory...

Regulatory News: EUROAPI (Paris:EAPI) posted today its 2023 Condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2023. This document is available for consultation and downloading on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports . This report includes notably the 2023 half-year activity report, the summary consolidated financial statements on 30 June 2023, and the Statutory Auditors’ review report on the...

Regulatory News: EUROAPI (Paris:EAPI): €496.6 million in Net Sales, up 2.6% 1 API Solutions (+0.2% sales growth, +1.9% with Other Clients, and -1.2% with Sanofi) pursued the deployment of its commercial roadmap, with 35 new clients added in H1 in both small and large molecules, the acceleration of the cross-selling strategy, and pricing optimization. H1 sales included the residual impact of the suspension of prostaglandin production in Budapest, which fully resumed in mid-April (approximately...